Amyotrophic lateral sclerosis: A review of current concepts

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 4, Issue 3, 2003, Pages 136-143

  Strong, Michael ^a   Rosenfeld, Jeffrey ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Dementia; Glutamate; Motor neuron disease; Neurofilament

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOSOMAL DOMINANT INHERITANCE; CELL ACTIVATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL OBSERVATION; COGNITIVE DEFECT; CYTOSKELETON; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ELECTROMYOGRAPHY; GENE MUTATION; HUMAN; INCIDENCE; LIFESPAN; MICROGLIA; MITOCHONDRION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SYMPTOM; TRANSGENIC MOUSE;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; COGNITION DISORDERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROBIOLOGY;

EID: 0141614840     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820310011250     Document Type: Review

References (74)

1. Charcot J, Joffroy A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux anterolateraux de la moelle epiniere. Arch Physiol Norm Pathol 1869; 2: 354-744.
2. Charcot J. De la sclerose laterale amytrophique. Prog. Med. 1874; 2: 325-327, 341-342, 453-455.
3. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis, ALS Consensus Conference, Airlie House, Warrington, Virginia, 1998. Vol. www.wfnals.org. World Federation of Neurology.
4. Kleopa KA, Sherman M, Neal B et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS [see comments]. Journal of the Neurological Sciences 1999; 164: 82-88.
5. Mazzini L, Corra T, Zaccala M et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Journal of Neurology 1995; 242: 695-698.
6. Chou S. Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. J Formos Med Assoc 1997; 96: 488-498.
7. Massman PJ, Sims J, Cooke N et al. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 1996; 61: 450-455.
8. Strong MJ, Grace GM, Orange JB et al. A prospective study of cognitive impairment in ALS. Neurology 1999; 53: 1665-1670.
9. Wilson CM, Grace GM, Munoz DG, et al. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multi-system disorder. Neurology 2001; 57: 651-657.
10. Hudson AJ, Davenport A, Hader WJ. The incidence of amyotrophic lateral sclerosis in southwestern Ontario, Canada. Neurology 1986; 36: 1524-1528.
11. Riggs JE. Longitudinal Gompertzian analysis of amyotrophic lateral sclerosis mortality in the U.S., 1977-1986: evidence for an inherently susceptible population subset. Mechanisms of Ageing & Development 1990; 55: 207-220.
12. Lilienfeld AM, Jacobs M, Willis M. A study of reproducibility of muscle testing and certain other aspects of muscle scoring. Physical Therapy Rev 1954; 34: 279.
13. Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989; 39: 768-773.
14. Provinciali L, Giovagnoli AR. Antecedent events in amyotrophic lateral sclerosis: do they influence clinical onset and progression? Neuroepidemiology 1990; 9: 255-262.
15. Garruto RM. Pacific paradigms of environmentally-induced neurological disorders: clinical, epidemiological and molecular perspectives. Neurotoxicology 1991; 12: 347-377.
16. Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam. Neurology 1985; 35: 193-198.
17. Plato CC, Garruto RM, Fox KM, Gajdusek DC. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam: a 25-year prospective case-control study. American Journal of Epidemiology 1986; 124: 643-656.
18. Granieri E, Carreras M, Tola R et al. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology 1988; 38: 1604-1608.
19. Rosati C, Pinna L, Granieri E et al. Studies on epidemiological, clinical, and etiological aspects of ALS disease in Sardinia, Southern Italy. Acta Neurologica Scandinavica 1977; 55: 231-244.
20. Giagheddu M, Puggioni G, Biancu F et al. Epidemiological study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol. Scand. 1983; 68: 394-404.
21. Bracco L, Antuono P, Amaducci L. Study of epidemiological and etiological factors of amyotrophic lateral sclerosis in the province of Florence, Italy. Acta Neurologica Scandinavica 1979; 60: 112-124.
22. Gunnarsson L, Palm R. Motor neuron disease and heavy manual labor: an epidemiological survey of Varmland County, Sweden. Neuroepidemiology 1984; 3: 195-206.
23. Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976; 26: 167-172.
24. Hawkes CH, Cavanagh JB, Fox AJ. Motoneuron disease: a disorder secondary to solvent exposure? Lancet 1989; 1: 73-76.
25. Strickland D, Smith SA, Dolliff G et al. Amyotrophic lateral sclerosis and occupational history. A pilot case-control study. Archives of Neurology 1996; 53: 730-733.
26. Abarbanel JM, Herishanu Y, Frisher S. Motor neuron disease in textile factory workers. Israel Journal of Medical Sciences 1985; 21: 924-925.
27. Cruz D, Nelson L, McGuire V, Longstreth WJ. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999; 18: 101-110.
28. Gallagher J, Sanders M. Trauma and amyotrophic lateral sclerosis: a report of 78 patients. Acta Neurologica Scandinavica 1987; 75: 145-150.
29. Riggs J. Antecedent trauma and amyotrophic lateral sclerosis in young adult men. Military Medicine 1993; 158: 55-57.
30. Riggs J. Trauma, axonal injury, and amyotrophic lateral sclerosis: a clinical correlate of a neuropharmacologic model. Clinical Neuropharmacology 1995; 18: 273-276.
31. McGuire V, Longstreth WT., Jr., Nelson LM et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. American Journal of Epidemiology 1997; 145: 1076-1088.
32. Strong M. Exogenous neurotoxins. In Brown RD, Jr., Meininger V. & Swash M, in (eds). Amyotrophic lateral sclerosis, Martin Dunitz Limited, London, 2000;279-287.
33. Nelson LM, McGuire V, Longstreth WT, Jr., Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. American Journal of Epidemiology 2000; 151: 156-163.
34. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis [see comments]. Muscle & Nerve 1989; 12: 833-841.
35. Eisen A, Schulzer M, MacNeil M et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle & Nerve 1993; 16: 27-32.
36. Strong MJ, Hudson AJ, Alvord WG. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Canadian Journal of Neurological Sciences 1991; 18: 45-58.
37. Cashman N, Cudkowicz M, Davidson M et al. Database APC. Gender effects on duration and onset age of amyotrophic lateral sclerosis. ALS and other motor neuron disorders 2. 2001: 41-42.
38. Brooks BR. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Journal of Neurological Sciences 1994; 124(Suppl): 96-107.
39. Ross MA, Miller RG, Berchert L et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50: 768-772.
40. Strong MJ. Simplifying the approach: what can we do? Neurology 1999; 53: S31-4; discussion S35-6.
41. Fujita K, Honda M, Hayashi R et al. Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. Journal of the Neurological Sciences 1998; 158: 53-57.
42. Heafield MT, Fearn S, Steventon GB et al. Plasma cysteine and sulphate levels in patients with motor neuron, Parkinson's and Alzheimer's disease. Neuroscience Letters 1990; 110: 216-220.
43. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurologica Scandinavica 1993; 88: 51-55.
44. Tumani H, Shen G, Peter JB, Bruck W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer's disease? Archives of Neurology 1999; 56: 1241-1246.
45. Stevens A, Weller M, Wietholter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 1993; 56: 361-364.
46. Younger DS, Rowland LP, Latov N et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 1990; 40: 595-599.
47. Norris FH, Burns W, U KS, Mukai E, Norris H. Spinal fluid cells and protein in amyotrophic lateral sclerosis. Archives of Neurology 1993; 50: 489-491.
48. Bogdanov M, Brown RH, Matson W et al. Increased oxidative damage to DNA in ALS patients. Free Radical Biology & Medicine 2000; 29: 652-658.
49. Beal MF, Ferrante RJ, Browne SE et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis [see comments]. Comment in: Ann Neurol 1999 Mar;45(3):413-414. Annals of Neurology 1997; 42: 644-654.
50. Tohgi H, Abe T, Yamazaki K et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Annals of Neurology 1999; 46: 129-131.
51. Tohgi H, Abe T, Yamazaki K et al. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neuroscience Letters 1999; 260: 204-206.
52. Hlzecka J, Stelmasiak Z, Dobosz B. Interleukin-1 beta converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica 2001; 103: 255-258.
53. Rosengren LE, Karlsson JE, Karlsson JO et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of Neurochemistry 1996; 67: 2013-2018.
54. Pestronk A, Adams RN, Clawson L et al. Serum antibodies to Gm1 Ganglioside In Amyotrophic Lateral Sclerosis. Neurology 1988; 38: 1457-1461.
55. Lamb NL, Patten BM. Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis and neuropathies. Muscle & Nerve 1991; 14: 1021-1027.
56. Sanders KA, Rowland LP, Murphy PL et al. Motor neuron diseases and amyotrophic lateral sclerosis: GM1 antibodies and paraproteinemia. Neurology 1993; 43: 418-420.
57. Fullmer H, Siedler H, Krooth R, Kurland L. A cutaneous disorder of connective tissue in amyotrophic lateral sclerosis. A histochemical study. Neurology 1960; 10: 717-724.
58. Ono S, Imai T, Takahashi K et al. Increased type III procollagen in serum and skin of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 1999; 100: 377-384.
59. Ono S, Imai T, Shimizu N, Nagao K. Increased expression of laminin 1 in the skin of amyotrophic lateral sclerosis. European Neurology 2000; 43: 215-220.
60. Ono S, Imai T, Takahashi K et al. Decreased type IV collagen of skin and serum in patients with amyotropic lateral sclerosis. Neurology 1998; 51: 114-120.
61. Ono S, Shimizu N, Imai T et al. Increased cystatin C immunoreactivity in the skin in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 2000; 102: 47-52.
62. Poloni M, Capitani E, Mazzini L, Ceroni M. Neuropsychological measures in amyotrophic lateral sclerosis and their relationship with CT scan-assessed cerebral atrophy. Acta Neurologica Scandinavica 1986; 74: 257-260.
63. Kew JJ, Goldstein LH, Leigh PN et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993; 116: 1399-1423.
64. Gallassi R, Montagna P, Morreale A et al. Neuropsychological, electroencephalogram and brain computed tomography findings in motor neuron disease. European Neurology 1989; 29: 115-120.
65. Ludolph AC, Elger CE, Bottger IW et al. N-isopropyl-p-1231-amphetamine single photon emission computer tomography in motor neuron disease. European Neurology 29: 255-260.
66. Waldemar G, Vorstrup S, Jensen TS et al. Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: a [99mTc]-d,1-HMPAO SPECT study. Journal of the Neurological Sciences 1992; 107: 19-28.
67. Talbot PR, Goulding PJ, Lloyd JJ et al. Inter-relation between classic motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study. Journal of Neurology, Neurosurgery & Psychiatry 1995; 58: 541-547.
68. Tanaka M, Kondo S, Hirai S et al. Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1993; 120: 22-28.
69. Ludolph AC, Langen KJ, Regard M et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurologica Scandinavica 1992; 85: 81-89.
70. Abrahams S, Goldstein LH, Lloyd CM et al. Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation. Journal of the Neurological Sciences 1995; 129: 54-55.
71. Abrahams S, Leigh PN, Kew JJ et al. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1995; 129: 44-46.
72. Strong MJ, Grace GM, Orange JB, Leeper HA. Cognition, language, and speech in amyotrophic lateral sclerosis: a review. Journal of Clinical & Experimental Neuropsychology 1996; 18: 291-303.
73. Strong M. The evidence for ALS as a multisystems disorder of limited phenotypic expression. Can J Neurol Sci 2001; 28: 283-298.
74. Julien JP. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 2001; 104: 581-591.